[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxdaxqLrqgcH9--BcEOmaedxsB-apbJ2owSFDm00Y6_s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"University of Turku",[4],119,false,18,4,138731,0,97,[14,17,20,22,24,27,29,31],{"name":15,"count":16},"Atrial Fibrillation",10,{"name":18,"count":19},"Healthy",5,{"name":21,"count":9},"Coronary Artery Disease",{"name":23,"count":9},"Physical Activity",{"name":25,"count":26},"Cardiovascular Diseases",3,{"name":28,"count":26},"Leadership",{"name":30,"count":26},"Dental Caries",{"name":32,"count":26},"Stroke",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,102,125,160,179,197,223,251,269,294,318,342,367,393,411,429,465,487,505,523,541,566,584,619,647,665,683,701,726,751],{"intervention":43,"totalTrials":9,"cells":44},"Dexmedetomidine",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":61,"PHASE3":63,"PHASE4":75,"NA":100},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[49],{"nctId":50,"briefTitle":51,"status":52,"phases":53,"primaryCompletion":54,"completion":54,"start":55,"enrollment":56,"conditions":57,"interventions":59},"NCT01084473","Effect of Dexmedetomidine on Gastric Emptying and Gastrointestinal Transit","COMPLETED",[36],"2010-06","2010-03",12,[58,18],"Gastric Emptying",[43,60],"Morphine",{"trials":62,"activeCount":11},[],{"trials":64,"activeCount":11},[65],{"nctId":66,"briefTitle":67,"status":52,"phases":68,"primaryCompletion":69,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":74},"NCT00714857","Population Pharmacokinetics of Dexmedetomidine in ICU Patients",[37,38],"2010-12","2007-10",21,[73],"Pharmacokinetics",[43],{"trials":76,"activeCount":11},[77,88],{"nctId":78,"briefTitle":79,"status":52,"phases":80,"primaryCompletion":81,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":86},"NCT01889004","The Neural Mechanisms of Anesthesia and Human Consciousness",[39],"2016-01","2014-02",47,[85],"Consciousness, Level Altered",[43,87],"Propofol",{"nctId":89,"briefTitle":90,"status":52,"phases":91,"primaryCompletion":92,"completion":92,"start":81,"enrollment":93,"conditions":94,"interventions":97},"NCT02624401","The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)",[39],"2017-03-13",160,[95,96],"Anesthesia","Unconsciousness",[43,87,98,99],"S-ketamine","Sevoflurane",{"trials":101,"activeCount":11},[],{"intervention":87,"totalTrials":103,"cells":104},2,{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":113,"NA":123},{"trials":106,"activeCount":11},[],{"trials":108,"activeCount":11},[],{"trials":110,"activeCount":11},[],{"trials":112,"activeCount":11},[],{"trials":114,"activeCount":11},[115,119],{"nctId":78,"briefTitle":79,"status":52,"phases":116,"primaryCompletion":81,"completion":81,"start":82,"enrollment":83,"conditions":117,"interventions":118},[39],[85],[43,87],{"nctId":89,"briefTitle":90,"status":52,"phases":120,"primaryCompletion":92,"completion":92,"start":81,"enrollment":93,"conditions":121,"interventions":122},[39],[95,96],[43,87,98,99],{"trials":124,"activeCount":11},[],{"intervention":126,"totalTrials":103,"cells":127},"colecalciferol",{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":147,"NA":158},{"trials":129,"activeCount":11},[],{"trials":131,"activeCount":11},[],{"trials":133,"activeCount":11},[],{"trials":135,"activeCount":11},[136],{"nctId":137,"briefTitle":138,"status":52,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},"NCT01432704","Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)",[37,38],"2011-05","2011-08","2008-03",70,[145],"Multiple Sclerosis",[126],{"trials":148,"activeCount":11},[149],{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":140,"completion":154,"start":142,"enrollment":143,"conditions":155,"interventions":156},"NCT01339676","Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)","UNKNOWN",[39],"2011-06",[145],[157],"Colecalciferol",{"trials":159,"activeCount":11},[],{"intervention":98,"totalTrials":161,"cells":162},1,{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":177},{"trials":164,"activeCount":11},[],{"trials":166,"activeCount":11},[],{"trials":168,"activeCount":11},[],{"trials":170,"activeCount":11},[],{"trials":172,"activeCount":11},[173],{"nctId":89,"briefTitle":90,"status":52,"phases":174,"primaryCompletion":92,"completion":92,"start":81,"enrollment":93,"conditions":175,"interventions":176},[39],[95,96],[43,87,98,99],{"trials":178,"activeCount":11},[],{"intervention":99,"totalTrials":161,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":195},{"trials":182,"activeCount":11},[],{"trials":184,"activeCount":11},[],{"trials":186,"activeCount":11},[],{"trials":188,"activeCount":11},[],{"trials":190,"activeCount":11},[191],{"nctId":89,"briefTitle":90,"status":52,"phases":192,"primaryCompletion":92,"completion":92,"start":81,"enrollment":93,"conditions":193,"interventions":194},[39],[95,96],[43,87,98,99],{"trials":196,"activeCount":11},[],{"intervention":198,"totalTrials":161,"cells":199},"amoxicillin-clavulanate",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":221},{"trials":201,"activeCount":11},[],{"trials":203,"activeCount":11},[],{"trials":205,"activeCount":11},[],{"trials":207,"activeCount":11},[],{"trials":209,"activeCount":11},[210],{"nctId":211,"briefTitle":212,"status":152,"phases":213,"primaryCompletion":214,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT00299455","Amoxicillin Clavulanate in Treatment of Acute Otitis Media",[39],"2008-12","2009-03","2006-03",320,[219],"Acute Otitis Media",[198],{"trials":222,"activeCount":11},[],{"intervention":224,"totalTrials":161,"cells":225},"Warfarin",{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":249},{"trials":227,"activeCount":11},[],{"trials":229,"activeCount":11},[],{"trials":231,"activeCount":11},[],{"trials":233,"activeCount":11},[],{"trials":235,"activeCount":11},[236],{"nctId":237,"briefTitle":238,"status":52,"phases":239,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":247},"NCT00479362","Anticoagulant Therapy During Pacemaker Implantation",[39],"2012-09","2005-09",447,[244,245,246],"Hemorrhage","Thrombosis","Embolism",[224,248],"Aspirin",{"trials":250,"activeCount":11},[],{"intervention":248,"totalTrials":161,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":267},{"trials":254,"activeCount":11},[],{"trials":256,"activeCount":11},[],{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[263],{"nctId":237,"briefTitle":238,"status":52,"phases":264,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":265,"interventions":266},[39],[244,245,246],[224,248],{"trials":268,"activeCount":11},[],{"intervention":270,"totalTrials":161,"cells":271},"daily intranasal administration of insulin",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":290,"NA":292},{"trials":273,"activeCount":11},[],{"trials":275,"activeCount":11},[],{"trials":277,"activeCount":11},[],{"trials":279,"activeCount":11},[280],{"nctId":281,"briefTitle":282,"status":152,"phases":283,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":289},"NCT00223613","Intranasal Insulin for Prevention of Type 1 Diabetes",[38],"2005-08","1997-08",240,[288],"Type 1 Diabetes",[270],{"trials":291,"activeCount":11},[],{"trials":293,"activeCount":11},[],{"intervention":295,"totalTrials":161,"cells":296},"docetaxel and capecitabine",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":298,"activeCount":11},[],{"trials":300,"activeCount":11},[],{"trials":302,"activeCount":11},[303],{"nctId":304,"briefTitle":305,"status":152,"phases":306,"primaryCompletion":215,"start":307,"enrollment":308,"conditions":309,"interventions":311},"NCT00669370","Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer",[37],"2006-06",50,[310],"Stomach Neoplasms",[295],{"trials":313,"activeCount":11},[],{"trials":315,"activeCount":11},[],{"trials":317,"activeCount":11},[],{"intervention":319,"totalTrials":161,"cells":320},"Ibandronic acid",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":322,"activeCount":11},[],{"trials":324,"activeCount":11},[],{"trials":326,"activeCount":11},[327],{"nctId":328,"briefTitle":329,"status":152,"phases":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT00381368","Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients",[37],"2006-10",60,[334],"Breast Cancer",[319],{"trials":337,"activeCount":11},[],{"trials":339,"activeCount":11},[],{"trials":341,"activeCount":11},[],{"intervention":343,"totalTrials":161,"cells":344},"Ropinirole",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":361,"PHASE4":363,"NA":365},{"trials":346,"activeCount":11},[],{"trials":348,"activeCount":11},[],{"trials":350,"activeCount":11},[351],{"nctId":352,"briefTitle":353,"status":152,"phases":354,"primaryCompletion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT00639119","Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type",[37],"2008-08","2007-08",16,[359],"Unverricht-Lundborg Syndrome",[343],{"trials":362,"activeCount":11},[],{"trials":364,"activeCount":11},[],{"trials":366,"activeCount":11},[],{"intervention":368,"totalTrials":161,"cells":369},"Bevacizumab",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":371,"activeCount":11},[],{"trials":373,"activeCount":11},[],{"trials":375,"activeCount":11},[376],{"nctId":377,"briefTitle":378,"status":52,"phases":379,"primaryCompletion":214,"completion":380,"start":284,"enrollment":381,"conditions":382,"interventions":384},"NCT00308607","Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma",[37],"2009-04",27,[383],"Metastatic Melanoma",[368,385,386],"dacarbazine","interferon-alfa-2a",{"trials":388,"activeCount":11},[],{"trials":390,"activeCount":11},[],{"trials":392,"activeCount":11},[],{"intervention":385,"totalTrials":161,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":396,"activeCount":11},[],{"trials":398,"activeCount":11},[],{"trials":400,"activeCount":11},[401],{"nctId":377,"briefTitle":378,"status":52,"phases":402,"primaryCompletion":214,"completion":380,"start":284,"enrollment":381,"conditions":403,"interventions":404},[37],[383],[368,385,386],{"trials":406,"activeCount":11},[],{"trials":408,"activeCount":11},[],{"trials":410,"activeCount":11},[],{"intervention":386,"totalTrials":161,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":414,"activeCount":11},[],{"trials":416,"activeCount":11},[],{"trials":418,"activeCount":11},[419],{"nctId":377,"briefTitle":378,"status":52,"phases":420,"primaryCompletion":214,"completion":380,"start":284,"enrollment":381,"conditions":421,"interventions":422},[37],[383],[368,385,386],{"trials":424,"activeCount":11},[],{"trials":426,"activeCount":11},[],{"trials":428,"activeCount":11},[],{"intervention":430,"totalTrials":103,"cells":431},"Ketamine",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":433,"activeCount":11},[],{"trials":435,"activeCount":11},[436,447],{"nctId":437,"briefTitle":438,"status":52,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},"NCT01794975","Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline",[36],"2012-12","2012-08",8,[444],"Changes in Striatal [11C]ORM-13070 Binding.",[430,446],"Atomoxetine",{"nctId":448,"briefTitle":449,"status":52,"phases":450,"primaryCompletion":451,"completion":451,"start":452,"enrollment":16,"conditions":453,"interventions":454},"NCT01435213","Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline",[36],"2012-01","2011-09",[18],[455,446,430,456],"Atipamezole","Insulin",{"trials":458,"activeCount":11},[],{"trials":460,"activeCount":11},[],{"trials":462,"activeCount":11},[],{"trials":464,"activeCount":11},[],{"intervention":446,"totalTrials":103,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":468,"activeCount":11},[],{"trials":470,"activeCount":11},[471,475],{"nctId":437,"briefTitle":438,"status":52,"phases":472,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":473,"interventions":474},[36],[444],[430,446],{"nctId":448,"briefTitle":449,"status":52,"phases":476,"primaryCompletion":451,"completion":451,"start":452,"enrollment":16,"conditions":477,"interventions":478},[36],[18],[455,446,430,456],{"trials":480,"activeCount":11},[],{"trials":482,"activeCount":11},[],{"trials":484,"activeCount":11},[],{"trials":486,"activeCount":11},[],{"intervention":455,"totalTrials":161,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":490,"activeCount":11},[],{"trials":492,"activeCount":11},[493],{"nctId":448,"briefTitle":449,"status":52,"phases":494,"primaryCompletion":451,"completion":451,"start":452,"enrollment":16,"conditions":495,"interventions":496},[36],[18],[455,446,430,456],{"trials":498,"activeCount":11},[],{"trials":500,"activeCount":11},[],{"trials":502,"activeCount":11},[],{"trials":504,"activeCount":11},[],{"intervention":456,"totalTrials":161,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":508,"activeCount":11},[],{"trials":510,"activeCount":11},[511],{"nctId":448,"briefTitle":449,"status":52,"phases":512,"primaryCompletion":451,"completion":451,"start":452,"enrollment":16,"conditions":513,"interventions":514},[36],[18],[455,446,430,456],{"trials":516,"activeCount":11},[],{"trials":518,"activeCount":11},[],{"trials":520,"activeCount":11},[],{"trials":522,"activeCount":11},[],{"intervention":60,"totalTrials":161,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":526,"activeCount":11},[],{"trials":528,"activeCount":11},[529],{"nctId":50,"briefTitle":51,"status":52,"phases":530,"primaryCompletion":54,"completion":54,"start":55,"enrollment":56,"conditions":531,"interventions":532},[36],[58,18],[43,60],{"trials":534,"activeCount":11},[],{"trials":536,"activeCount":11},[],{"trials":538,"activeCount":11},[],{"trials":540,"activeCount":11},[],{"intervention":542,"totalTrials":161,"cells":543},"Intravenous dexmedetomidine",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":564},{"trials":545,"activeCount":11},[],{"trials":547,"activeCount":11},[548],{"nctId":549,"briefTitle":550,"status":52,"phases":551,"primaryCompletion":552,"completion":552,"start":215,"enrollment":553,"conditions":554,"interventions":556},"NCT00837187","Bioavailability of Dexmedetomidine After Intranasal Administration",[36],"2009-05",7,[555],"Sedation",[542,557],"Intranasal dexmedetomidine",{"trials":559,"activeCount":11},[],{"trials":561,"activeCount":11},[],{"trials":563,"activeCount":11},[],{"trials":565,"activeCount":11},[],{"intervention":557,"totalTrials":161,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":569,"activeCount":11},[],{"trials":571,"activeCount":11},[572],{"nctId":549,"briefTitle":550,"status":52,"phases":573,"primaryCompletion":552,"completion":552,"start":215,"enrollment":553,"conditions":574,"interventions":575},[36],[555],[542,557],{"trials":577,"activeCount":11},[],{"trials":579,"activeCount":11},[],{"trials":581,"activeCount":11},[],{"trials":583,"activeCount":11},[],{"intervention":585,"totalTrials":103,"cells":586},"prednisolone",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":595,"NA":607},{"trials":588,"activeCount":11},[],{"trials":590,"activeCount":11},[],{"trials":592,"activeCount":11},[],{"trials":594,"activeCount":11},[],{"trials":596,"activeCount":11},[597],{"nctId":598,"briefTitle":599,"status":152,"phases":600,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":606},"NCT00494624","Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children",[39],"2008-05","2000-09",300,[605],"Wheezing",[585],{"trials":608,"activeCount":11},[609],{"nctId":610,"briefTitle":611,"status":152,"phases":612,"primaryCompletion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT00731575","Viral Inception of Asthma: Prospective Study From Infancy to School-age",[40],"2016-05","2007-06",200,[617],"Asthma",[585],{"intervention":620,"totalTrials":161,"cells":621},"0,1 mg\u002Fkg of oxycodone",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":623,"activeCount":11},[],{"trials":625,"activeCount":11},[],{"trials":627,"activeCount":11},[],{"trials":629,"activeCount":11},[],{"trials":631,"activeCount":11},[],{"trials":633,"activeCount":11},[634],{"nctId":635,"briefTitle":636,"status":152,"phases":637,"primaryCompletion":638,"completion":69,"start":639,"enrollment":640,"conditions":641,"interventions":643},"NCT00733083","A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients",[40],"2009-12","2008-09",100,[642],"Post Tonsillectomy Pain",[620,644,645,646],"Morphine 0,1 mg\u002Fkg","Dexamethasone 0,5 mg\u002Fkg","NaCl 0,9%",{"intervention":644,"totalTrials":161,"cells":648},{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":650,"activeCount":11},[],{"trials":652,"activeCount":11},[],{"trials":654,"activeCount":11},[],{"trials":656,"activeCount":11},[],{"trials":658,"activeCount":11},[],{"trials":660,"activeCount":11},[661],{"nctId":635,"briefTitle":636,"status":152,"phases":662,"primaryCompletion":638,"completion":69,"start":639,"enrollment":640,"conditions":663,"interventions":664},[40],[642],[620,644,645,646],{"intervention":645,"totalTrials":161,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":675,"NA":677},{"trials":668,"activeCount":11},[],{"trials":670,"activeCount":11},[],{"trials":672,"activeCount":11},[],{"trials":674,"activeCount":11},[],{"trials":676,"activeCount":11},[],{"trials":678,"activeCount":11},[679],{"nctId":635,"briefTitle":636,"status":152,"phases":680,"primaryCompletion":638,"completion":69,"start":639,"enrollment":640,"conditions":681,"interventions":682},[40],[642],[620,644,645,646],{"intervention":646,"totalTrials":161,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":686,"activeCount":11},[],{"trials":688,"activeCount":11},[],{"trials":690,"activeCount":11},[],{"trials":692,"activeCount":11},[],{"trials":694,"activeCount":11},[],{"trials":696,"activeCount":11},[697],{"nctId":635,"briefTitle":636,"status":152,"phases":698,"primaryCompletion":638,"completion":69,"start":639,"enrollment":640,"conditions":699,"interventions":700},[40],[642],[620,644,645,646],{"intervention":702,"totalTrials":161,"cells":703},"Anticoagulation Therapy",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":705,"activeCount":11},[],{"trials":707,"activeCount":11},[],{"trials":709,"activeCount":11},[],{"trials":711,"activeCount":11},[],{"trials":713,"activeCount":11},[],{"trials":715,"activeCount":11},[716],{"nctId":717,"briefTitle":718,"status":152,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT04001205","Atrial Fibrillation Burden and Long-term Risk of Thromboembolic Complications- the FinCV-4 Study",[],"2025-01-08","2019-06-01",1300,[15,724],"Stroke, Ischemic",[702],{"intervention":727,"totalTrials":161,"cells":728},"Fluoxetine",{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":730,"activeCount":11},[],{"trials":732,"activeCount":11},[],{"trials":734,"activeCount":11},[],{"trials":736,"activeCount":11},[],{"trials":738,"activeCount":11},[],{"trials":740,"activeCount":11},[741],{"nctId":742,"briefTitle":743,"status":52,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT00714779","Fluoxetine vs. Brief Psychotherapy for Major Depression",[40],"2004-12","2000-01",85,[749],"Major Depressive Disorder",[727],{"intervention":752,"totalTrials":161,"cells":753},"docetaxel + CEF",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":755,"activeCount":11},[],{"trials":757,"activeCount":11},[],{"trials":759,"activeCount":11},[],{"trials":761,"activeCount":11},[],{"trials":763,"activeCount":11},[],{"trials":765,"activeCount":11},[766],{"nctId":767,"briefTitle":768,"status":52,"phases":769,"primaryCompletion":770,"completion":215,"start":771,"enrollment":772,"conditions":773,"interventions":778},"NCT01110291","Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events",[],"2004-01","2003-04",20,[774,775,776,777],"CYP3A Phenotyping","CYP3A5 and MDR1 Genotyping","Docetaxel Toxicity","Associations Between Genetic Data and Docetaxel Toxicity",[752]]